Renaissance Technologies LLC lifted its holdings in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 3.6% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 197,500 shares of the medical research company’s stock after acquiring an additional 6,900 shares during the quarter. Renaissance Technologies LLC’s holdings in Natera were worth $39,498,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors also recently bought and sold shares of NTRA. Reflection Asset Management purchased a new stake in shares of Natera during the 4th quarter valued at about $29,000. Palladiem LLC purchased a new position in shares of Natera during the fourth quarter valued at approximately $31,000. Horizon Investments LLC bought a new position in Natera during the third quarter valued at approximately $32,000. International Assets Investment Management LLC lifted its position in Natera by 132.9% during the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 97 shares during the period. Finally, Bank of Jackson Hole Trust boosted its holdings in Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after purchasing an additional 83 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
NTRA has been the subject of a number of research analyst reports. Wolfe Research started coverage on shares of Natera in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 target price for the company. BTIG Research set a $275.00 price target on Natera and gave the company a “buy” rating in a report on Wednesday, June 24th. William Blair started coverage on Natera in a report on Tuesday, April 14th. They issued an “outperform” rating for the company. Piper Sandler reaffirmed an “overweight” rating and issued a $249.00 price objective on shares of Natera in a report on Tuesday, May 12th. Finally, Royal Bank Of Canada began coverage on Natera in a research report on Thursday, June 11th. They set an “outperform” rating and a $275.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and an average price target of $267.83.
Natera Trading Down 1.5%
NTRA opened at $258.03 on Tuesday. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $288.04. The company has a market capitalization of $36.95 billion, a PE ratio of -158.30 and a beta of 1.51. The firm’s 50 day simple moving average is $242.06 and its two-hundred day simple moving average is $221.57.
Insider Activity
In related news, CEO Steven Leonard Chapman sold 41,124 shares of Natera stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the transaction, the chief executive officer directly owned 108,743 shares in the company, valued at approximately $24,035,465.29. The trade was a 27.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $272.90, for a total value of $818,700.00. Following the completion of the sale, the insider owned 134,643 shares of the company’s stock, valued at approximately $36,744,074.70. The trade was a 2.18% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 167,171 shares of company stock worth $37,239,209. Company insiders own 5.05% of the company’s stock.
About Natera
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Read More
- Five stocks we like better than Natera
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
